|The impact of comorbidity on cancer and its treatment|
D Sarfati, B Koczwara, C Jackson
CA: a cancer journal for clinicians 66 (4), 337-350, 2016
|Measuring cancer survival in populations: relative survival vs cancer-specific survival|
D Sarfati, T Blakely, N Pearce
International journal of epidemiology 39 (2), 598-610, 2010
|SF‐36 health survey reliability, validity and norms for New Zealand|
KM Scott, MI Tobias, D Sarfati, SJ Haslett
Australian and New Zealand journal of public health 23 (4), 401-406, 1999
|Survival disparities in Indigenous and non-Indigenous New Zealanders with colon cancer: the role of patient comorbidity, treatment and health service factors|
S Hill, D Sarfati, T Blakely, B Robson, G Purdie, J Chen, E Dennett, ...
Journal of Epidemiology & Community Health 64 (2), 117-123, 2010
|Global cancer incidence in older adults, 2012 and 2035: a population‐based study|
S Pilleron, D Sarfati, M Janssen‐Heijnen, J Vignat, J Ferlay, F Bray, ...
International journal of cancer 144 (1), 49-58, 2019
|The effect of comorbidity on the use of adjuvant chemotherapy and survival from colon cancer: a retrospective cohort study|
D Sarfati, S Hill, T Blakely, B Robson, G Purdie, E Dennett, D Cormack, ...
BMC cancer 9 (1), 1-10, 2009
|Review of methods used to measure comorbidity in cancer populations: no gold standard exists|
Journal of clinical epidemiology 65 (9), 924-933, 2012
|A challenge to the cross-cultural validity of the SF-36 health survey: Factor structure in Māori, Pacific and New Zealand European ethnic groups|
KM Scott, D Sarfati, MI Tobias, SJ Haslett
Social Science & Medicine 51 (11), 1655-1664, 2000
|Does the frame affect the picture? A study into how attitudes to screening for cancer are affected by the way benefits are expressed|
D Sarfati, P Howden-Chapman, A Woodward, C Salmond
Journal of Medical Screening 5 (3), 137-140, 1998
|Indigenous inequalities in cancer: what role for health care?|
S Hill, D Sarfati, B Robson, T Blakely
ANZ journal of surgery 83 (1-2), 36-41, 2013
|Ethnicity and management of colon cancer in New Zealand: do indigenous patients get a worse deal?|
S Hill, D Sarfati, T Blakely, B Robson, G Purdie, E Dennett, D Cormack, ...
Cancer 116 (13), 3205-3214, 2010
|Cannabis exposure and risk of testicular cancer: a systematic review and meta-analysis|
J Gurney, C Shaw, J Stanley, V Signal, D Sarfati
BMC cancer 15 (1), 1-10, 2015
|Socioeconomic inequalities in cancer survival in New Zealand: the role of extent of disease at diagnosis|
M Jeffreys, D Sarfati, V Stevanovic, M Tobias, C Lewis, N Pearce, ...
Cancer Epidemiology and Prevention Biomarkers 18 (3), 915-921, 2009
|Consideration of comorbidity in treatment decision making in multidisciplinary cancer team meetings: a systematic review|
J Stairmand, L Signal, D Sarfati, C Jackson, L Batten, M Holdaway, ...
Annals of Oncology 26 (7), 1325-1332, 2015
|The impact of patient comorbidity on cancer stage at diagnosis|
J Gurney, D Sarfati, J Stanley
British journal of cancer 113 (9), 1375-1380, 2015
|Risk factors for cryptorchidism|
JK Gurney, KA McGlynn, J Stanley, T Merriman, V Signal, C Shaw, ...
Nature Reviews Urology 14 (9), 534, 2017
|Cancer-specific administrative data–based comorbidity indices provided valid alternative to Charlson and National Cancer Institute Indices|
D Sarfati, J Gurney, J Stanley, C Salmond, P Crampton, E Dennett, J Koea, ...
Journal of clinical epidemiology 67 (5), 586-595, 2014
|Cancer survival in the context of mental illness: a national cohort study|
R Cunningham, D Sarfati, J Stanley, D Peterson, S Collings
General Hospital Psychiatry 37 (6), 501-506, 2015
|Changing global policy to deliver safe, equitable, and affordable care for women’s cancers|
O Ginsburg, R Badwe, P Boyle, G Derricks, A Dare, T Evans, A Eniu, ...
The Lancet 389 (10071), 871-880, 2017
|The association of active smoking with multiple cancers: national census-cancer registry cohorts with quantitative bias analysis|
T Blakely, JJ Barendregt, RH Foster, S Hill, J Atkinson, D Sarfati, ...
Cancer Causes & Control 24 (6), 1243-1255, 2013